Browsing Tag
BeOne Medicines
6 posts
Zymeworks (ZYME) to buy Theravance (TBPH) for $929m in cash plus ampreloxetine CVR
Zymeworks (ZYME) to acquire Theravance (TBPH) for $17/share plus CVR, $929M equity value. Non-recourse OMERS financing minimises ZYME's cash at risk.
BeOne Medicines wins FDA Priority Review for TEVIMBRA in HER2-positive GEA as ONC stock faces trial-to-approval test
BeOne has survival data and FDA momentum. The bigger question is whether TEVIMBRA can change first-line HER2-positive GEA care.
Why BeOne Medicines (ONC) just strengthened its China oncology play with Imdelltra approval
BeOne Medicines wins China approval for Amgen’s Imdelltra in lung cancer. Read why this matters for ONC, competition, and China oncology growth.
Senhwa Biosciences strikes pivotal supply deal with BeOne Medicines for cold tumor breakthrough
Senhwa Biosciences and BeOne Medicines announce a global clinical trial to tackle cold tumors. Find out how this deal could change cancer immunotherapy.
Can BeOne’s sonrotoclax become the new backbone of B-cell cancer treatment?
Find out how BeOne Medicines’ sonrotoclax is redefining lymphoma and leukemia treatment with new ASH 2025 data.
BeOne Medicines’ sonrotoclax trial hits primary endpoint in mantle cell lymphoma patients
BeOne Medicines’ sonrotoclax met its primary endpoint in mantle cell lymphoma, with positive Phase 1/2 trial results. Find out what this means for patients.